OpenLobby.EU
Explore

Tuberculosis Vaccine Initiative

TBVI

To support, integrate, translate and prioritise R&D efforts to discover and develop new tuberculosis vaccines that are accessible and affordable for all.

Lobbying Activity

Response to Recommendation for strengthened actions against antimicrobial resistance

17 Mar 2022

The TuBerculosis Vaccine Initiative (TBVI) welcomes the opportunity to comment on the European Commission’s call for evidence on antimicrobial resistance. TB remains one of the deadliest infectious disease in the world, killing 1.5 million each year. Around 10 million people develop TB disease annually. Drug-resistant tuberculosis is the leading contributor to deaths from antimicrobial resistance, accounting for one fourth of all AMR-related deaths. New, safe and effective TB vaccines are an essential component of the global strategy to address the deadly threat of antimicrobial resistance as they would reduce the need for antibiotics. Please find attached our response and recommendations.
Read full response

Meeting with Vytenis Andriukaitis (Commissioner) and

18 Sept 2018 · TB, UN high level meeting on TB

Meeting with Robert-Jan Smits (Director-General Research and Innovation)

17 Oct 2016 · TB Vaccine R&D and H2020 programme

Meeting with Carlos Moedas (Commissioner)

16 Jul 2015 · Presentation of TBVI activities